Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 2/20 | 0.48 |
| ▸ | MAP3K14 | Q99558 | 3/20 | 0.48 |
| ▸ | CDK2 | P24941 | 5/20 | 0.45 |
| ▸ | CDC7 | O00311 | 3/20 | 0.45 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 7/20 | 0.44 |
| ▸ | PRKACA | P17612 | 5/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.42 |
| ▸ | CDK1 | P06493 | 4/20 | 0.42 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.42 |
| ▸ | PRKACG | P22612 | 3/20 | 0.42 |
| ▸ | PRKACB | P22694 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30775416 | 0.85 | MAP3K14 (0.57) | FEN1MAP3K14CDK2CDC7GSK3B | |
| SCHEMBL2649419 | 0.83 | KMO (0.40) | FEN1MAP3K14CDK2CDC7DBF4 | |
| SCHEMBL5803933 | 0.79 | CDK1 (0.58) | MAP3K14CDK2CCNE1GSK3BPRKACA | |
| SCHEMBL5140478 | 0.79 | FEN1 (0.57) | FEN1MAP3K14CDK2CDC7DBF4 | |
| SCHEMBL30353577 | 0.79 | FEN1 (0.57) | FEN1MAP3K14CDK2CDC7DBF4 | |
| SCHEMBL18495641 | 0.77 | CLK1 (0.60) | FEN1MAP3K14CDK2CDC7DBF4 | |
| SCHEMBL2650530 | 0.76 | MAP4K4 (0.43) | CDK2GSK3BPRKACAHSP90AA1ADORA2A | |
| SCHEMBL17292996 | 0.76 | MAPT (0.56) | MAP3K14CDK2CDC7DBF4CCNE1 | |
| SCHEMBL20467870 | 0.76 | MAP3K14 (0.45) | FEN1MAP3K14CDK2CCNE1GSK3B | |
| SCHEMBL27159221 | 0.75 | FEN1 (0.54) | FEN1MAP3K14CDK2CDC7GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3331885-B1 | COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-12-23 | — | — | EP | disclosed |
| EP-3331885-B1 | COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-12-23 | — | — | EP | disclosed |
| CN-108137599-B | Compound (I) | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-10-27 | — | — | CN | disclosed |
| US-10479792-B2 | Compounds | GiaxoSmithKline Intellectual Property Development Limited (GB) | 2019-11-19 | — | — | US | disclosed |
| US-10479792-B2 | Compounds | GiaxoSmithKline Intellectual Property Development Limited (GB) | 2019-11-19 | — | — | US | disclosed |
| US-20180222911-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-08-09 | — | — | US | disclosed |
| US-20180222911-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-08-09 | — | — | US | disclosed |
| US-20180222911-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-08-09 | — | — | US | disclosed |
| EP-3331885-A1 | COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017025416-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-02-16 | — | — | WO | disclosed |
| WO-2017025416-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222911-A1 | COMPOUNDS | TBCA, MPO, GOT1 | FEN1 4607/4885MAP3K14 2152/4885CDK2 4457/4885 |
| US-10479792-B2 | Compounds | TBCA, MPO, GOT1 | FEN1 4607/4885MAP3K14 2152/4885CDK2 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.